Double Deficiency for RORγt and T-bet Drives Th2-Mediated Allograft Rejection in Mice


J Immunol published online 20 September 2013
http://www.jimmunol.org/content/early/2013/09/20/jimmunol.1301741

Supplementary Material
http://www.jimmunol.org/content/suppl/2013/09/24/jimmunol.1301741.DC1

Subscription
Information about subscribing to The Journal of Immunology is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Double Deficiency for RORγt and T-bet Drives Th2-Mediated Allograft Rejection in Mice


Although Th1, Th2, and Th17 cells are thought to be major effector cells in adaptive alloimmune responses, their respective contribution to allograft rejection remains unclear. To precisely address this, we used mice genetically modified for the Th1 and Th17 hallmark transcription factors T-bet and RORγt, respectively, which allowed us to study the alloreactive role of each subset in an experimental transplant setting. We found that in a fully mismatched heterotopic mouse heart transplantation model, T cells deficient for T-bet (prone to Th17 differentiation) versus RORγt (prone to Th1 differentiation) rejected allografts at a more accelerated rate, indicating a predominance of Th17- over Th1-driven alloimmunity. Importantly, T cells doubly deficient for both T-bet and RORγt differentiated into alloreactive GATA-3-expressing Th2 cells, which promptly induced allograft rejection characterized by a Th2-type intragraft expression profile and eosinophilic infiltration. Mechanistically, Th2-mediated allograft rejection was contingent on IL-4, as its neutralization significantly prolonged allograft survival by reducing intragraft expression of Th2 effector molecules and eosinophilic allograft infiltration. Moreover, under IL-4-neutralizing conditions, alloreactive double-deficient T cells upregulated Eomesodermin (Eomes) and IFN-γ, but not GATA-3. Thus, in the absence of T-bet and RORγt, Eomes may salvage Th1-mediated alloimmunity that underlies IL-4 neutralization-resistant allograft rejection. We summarize that, whereas Th17 cells predictably promote allograft rejection, IL-4-producing GATA-3+ Th2 cells, which are generally thought to protect allogeneic transplants, may actually be potent facilitators of organ transplant rejection in the absence of T-bet and RORγt. Moreover, Eomes may rescue Th1-mediated allograft rejection in the absence of IL-4, T-bet, and RORγt. The Journal of Immunology, 2013, 191: 000–000.

C

D4+ Th cells play a critical role in driving alloimmune responses in bone marrow and solid organ transplantation (1). Depending on the cytokine milieu, CD4+ effector T cells primarily differentiate into a Th1, Th2, Th9, or Th17 phenotype with different cytokine profiles and distinct functions. Th1 differentiation is initiated through an IL-12/STAT4-mediated induction of the T-box transcription factor T-bet, leading to enhanced production of IFN-γ. Mechanistic studies demonstrated that, apart from regulating Th1 differentiation, T-bet also actively suppresses the Th2 cell-specific transcription factor GATA-3 (2, 3) and the Th17 hallmark transcription factor RORγt (4). In transplantation it is well established that graft-versus-host disease (GVHD) and allograft rejection are predominantly Th1 driven, but can also be mediated by Th17 cells (1, 5). The role of Th2 cells in alloimmunity, however, remains ambiguous. Whereas some studies suggested that Th2 cells can mediate GVHD and promote allograft rejection (6–9), recent data in T-bet (Th1) and RORγt (Th17) knockout models indicate that Th2 cell polarization may ameliorate acute GVHD and favor allograft survival (5, 10). Consistent with this idea, it was recently reported that mice deficient for both T-bet (Th1) and RORγt (Th17) fail to induce acute GVHD in bone marrow transplantation, suggesting only a minor role of Th2 cells in destructive alloimmune responses (10).

In this study, we initiated experiments in T-bet– and RORγt-deficient mice to test the effects of a Th2-predominant environment on organ transplant rejection, with expectations that Th2 cell predominance might protect organ allografts. To the contrary, we found that Th2 polarization does not promote tolerance in this model, but rather causes early severe heart and skin allograft rejection associated with eosinophilic infiltration. Such Th2-mediated allograft rejection was dependent on IL-4, neutralization of which induced Eomesodermin (Eomes)-expressing IFN-γ+ Th1 cells that may trigger anti–IL-4–resistant allograft rejection in the absence of T-bet and RORγt.

Materials and Methods

Mice generation

Six- to 8-wk-old wild-type (wt) (C57BL/6j and BALB/c) mice were purchased from Charles River Laboratories (Sulzfeld, Germany). RORγt−/− mice were purchased from Jackson Laboratories (via Charles River Laboratories) and crossed with T-bet−/− mice (Jackson Laboratories, via Charles River Laboratories). Genotyping confirmed the RORγt and T-bet deficiency. RAG common γ-chain (B6.Rag-γc) double knockout (DKO) mice were purchased from Taconic (Petersburgh, NY). Animal experiments were carried out according to the regional rules and regulations of Upper Palatinate, Germany.

The online version of this article contains supplemental material.

Abbreviations used in this article: DKO, double knockout; Eomes, Eomesodermin; GVHD, graft-versus-host disease; HTx, heart transplantation; STx, skin transplantation; wt, wild-type.

Department of Surgery, University Hospital Regensburg, University of Regensburg, 93053 Regensburg, Germany

Received for publication July 1, 2013. Accepted for publication August 18, 2013.

This work was supported by European Union 7th Framework Programme ONE Study Grant 266067 (to E.K.G., H.J.S., G.E.K., and A.K.) and Deutsche Forschungsgemeinschaft Grants KFO 243/1, KR 3631/2-1, and HIU 1836/2-1 (to E.K.G., H.J.S., G.E.K., and A.K.).

Address correspondence and reprint requests to Dr. Alexander Kroemer, Department of Surgery, University Hospital Regensburg, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany. E-mail address: alexander.kroemer@ukr.de

The Journal of Immunology

0022-1767/13 $16.00

2013 by The American Association of Immunologists, Inc.

doi:10.4049/jimmunol.1301741

0000–000
Skin and heart transplant model, adoptive transfer, and Ab treatment

In a MHC full-mismatched model, B6.RAG-yc mice were used as recipients of BALB/c tail skin or heart allografts. Skin transplantation (STx) and rejection scoring were performed, as previously described (6, 11, 12). Abdominal heterotopic heart transplantation (HTx) and assay of graft function were done, as described (5, 13). Seven days after transplantation, purified CD3+ T cells (2 × 10^6) from the various mouse strains were adoptively transferred via the tail vein into the STx or HTx recipients. Neutralizing IL-4 mAb (clone 11B11; BioXCell) was administered i.p. at a dosage of 1 mg on days 0, 2, 4, and 7 after T cell transfer, followed by weekly applications.

Histology

Skin and heart allografts were harvested at day 10 or at the time of rejection, respectively. The grafts were embedded, transversely sectioned, and then H&E stained.

CD4* Th cell differentiation in vitro

Flow cytometer–sorted CD4* T cells recovered from wt, T-bet−/−, RORγt−/−, and RORγt−/−T-bet−/− mice were reconstituted into BALB/c recipients of BALB/c STx. Skin grafts were promptly rejected by all mice deficient for T-bet or T-bet and RORγt knockout animals. To reverse T cell alloreactivity, we adopted transferred mRORγt−/− mice expressing high GFP levels, demonstrating proper Rorc-reporter function (Fig. 1A). Next, we tested T cell effector capabilities in the absence of T-bet, RORγt, or both genes by polarizing flow cytometer–sorted CD4* T cells from wt, T-bet−/−, RORγt−/−, and RORγt−/−T-bet−/− mice toward a Th1 or Th17 phenotype. To assess polarization, expression levels of the Th1 and Th17 effector cytokines IFN-γ and IL-17A, respectively, were measured by flow cytometry and RT-PCR or ELISA after 5 d of culture. In the absence of T-bet, CD4* T cells express relatively high IL-17A levels under Th17 conditions and expected low levels of IFN-γ under Th1-polarizing conditions (Fig. 1B, 1C). In contrast, T cells knocked out for RORγt produce high levels of IFN-γ when polarized toward the Th1 phenotype and low levels of IL-17A under Th17 conditions (Fig. 1B, 1C). Importantly, in T cells from RORγt−/− mice, we found substantially lower IL-17A and IFN-γ expression levels under Th17 conditions, and were secondarily measured by flow cytometry, RT-PCR, or ELISA when compared with T-bet−/− T cells (Fig. 1B, 1C). These results highlight the significance of RORγt and T-bet for Th17 and Th17 differentiation, which is in line with previous studies (17, 18).

Double deficiency for T-bet and RORγt promotes alloreactive Th2 cell differentiation in vivo

To evaluate the contribution of alloreactive Th1 versus Th17 cells in acute allograft rejection in a well-established allosensitization model in vivo, we adoptively transferred purified T cells from the various T-bet and RORγt knockout animals into B6.RAG-yc−/− recipients of a fully matched BALB/c STx. Skin grafts were promptly rejected by all mice deficient for T-bet or T-bet and RORγt (Fig. 2A). T cells single deficient for RORγt promoted a weaker rejection response, with a nonsignificant trend toward prolongation of graft survival. Detailed studies of allografts and T cells recovered from the groups of STx recipients at the time of rejection revealed important differences. Consistent with our in vitro results, recovered and ex vivo restimulated T cells from RORγt−/− mice expressed relatively high IFN-γ levels, whereas low expression levels of IL-17A were evident (Fig. 2B, 2C). Recovered T cells from mice receiving T-bet−/− T cells had a reciprocal expression pattern (Fig. 2B, 2C). Moreover, STx recipients generated RORγt−/− and T-bet−/− cells also differed in their expression of the Th2 signature cytokine IL-4; RORγt−/− T cells produced lower levels of IL-4 when compared with T-bet−/− T cells (Fig. 2B, 2C). Critically, recipients transferred with RORγt−/− mice featured diminished levels of IL-17A and IFN-γ, but appreciable levels of IL-4 and GATA-3 consistent with a strong Th2 allorresponse (Fig. 2B, 2C). Histology of rejecting skin allografts from recipients transferred with T cells from RORγt−/− mice revealed a conventional mononuclear cell infiltration as opposed to the predominantly polymorphonuclear cell infiltration (including eosinophils and neutrophils) in skin grafts from recipients reconstituted with T cells from T-bet−/− and RORγt−/−T-bet−/− mice (Fig. 2D).

Double deficiency for T-bet and RORγt promotes Th2-mediated accelerated heart allograft rejection akin to single deficiency for T-bet

A recent study by Yu et al. (10) demonstrated that a double deficiency for T-bet and RORγt prevents acute GVHD development in a full-mismatch murine model of hematopoietic stem cell transplantation. Due to their inability to differentiate into Th1 and...
Th17 phenotypes, T cells in these mice preferentially commit to a Th2 fate that may be protolerogenic and protect from GVHD (10). Considering this, we tested the hypothesis in organ transplantation that Th2-oriented cells from ROR\textsubscript{g }tgfp/gfpT-bet\textsuperscript{2/2} mice will protect heart transplants from acute rejection. Unexpectedly, flow cytometer–sorted T cells from ROR\textsubscript{g }tgfp/gfpT-bet\textsuperscript{2/2} mice transferred into B6.RAG-yc\textsuperscript{2/2} recipients of fully mismatched BALB/c heart allografts rejected promptly (22.8 ± 3.7 d; Fig. 3A), as well as HTx recipients given T-bet\textsuperscript{2/2} T cells (19.8 ± 6.47 d; Fig. 3A). Surprisingly, HTx recipients given T cells from ROR\textsubscript{g }tgfp/gfp mice failed to acutely reject their allografts with the majority (63%, n = 8) surviving long-term; prolonged allograft survival was associated with low levels of IL-17A and IL-4 and increased IFN-\gamma expression (Fig. 3B, 3C). In accordance with the data obtained in our STx model, T-bet\textsuperscript{2/2} T cell recipients expressed relatively high levels of IL-17A and low IFN-\gamma (Fig. 3B). Consistent with previous studies (5), T-bet\textsuperscript{2/2} T cell recipients also showed enhanced intragraft mRNA expression of the Th2-related cytokines IL-4, IL-5, and IL-13, as well as the Th2 transcription factor GATA-3 (Fig. 3D). ROR\textsubscript{g }tgfp/gfpT-bet\textsuperscript{2/2} T cell recipients exhibited low expression of IFN-\gamma and IL-17A, whereas IL-4 levels were relatively increased (Fig. 3B, 3C); these results are consistent with the intragraft mRNA cytokine expression pattern (Fig. 3D). To study potential involvement of Th9 cells in the rejection process, we also measured the intragraft mRNA expression levels of IL-9. Interestingly, mRNA expression of IL-9 was very low without any differences between the various mouse strains (data not shown).

Similar to STx, HTx mice with T cells from T-bet\textsuperscript{2/2} and ROR\textsubscript{g }tgfp/gfpT-bet\textsuperscript{2/2} mice were heavily infiltrated with eosinophilic and only few neutrophilic granulocytes, indicating a predominance of the Th2 phenotype in these mice compared with the mononuclear cell infiltration of recipients given ROR\textsubscript{g }tgfp/gfp T cells (Fig. 3E).
Th2-mediated allograft rejection in the absence of T-bet and RORγt is mediated by IL-4

To show the importance of Th2 responses, we tested whether neutralization of IL-4 with anti–IL-4 Ab would prolong HTx allograft survival in B6.RAG-2−/− mice. Importantly, IL-4 neutralization prolonged allograft survival (gated on viable CD3+CD4+ cells, logrank survival in B6.RAG-2−/− mice. Control recipients received no cell transfer (n = 5 each). (B) Representative flow cytometry analyses of intracellular IL-17A and IFN-γ (top) as well as IL-4 and GATA-3 (bottom) expression in ex vivo restimulated (PMA, ionomycin) splenic CD4+ T cells from the adoptively transferred STx recipients (gated on viable CD3+CD4+ cells, n = 5). (C) IL-17A protein expression in supernatants of ex vivo restimulated splenocytes from the adoptively transferred STx recipients (ELISA, n = 5 each). (D) Representative histology (H&E staining, scale bars = 20 μm) of rejecting skin allografts (day 10 postinjection). *p < 0.05, **p < 0.005.

Discussion

Studies in genetically modified mice have shown that T cells deficient for T-bet (non-Th1) preferentially differentiate into Th2 and Th17 effector cells (5, 10), resulting in an aggressive alloimmune response against solid organ and hematopoietic stem cell transplants. Moreover, T cells deficient for RORγt (non-Th17) are prone to Th1 differentiation, also leading to GVHD after bone marrow transplantation (1, 10). In our transfer model of full-mismatched skin and heart transplantation, we found that double deficiency for Th1 and Th17 favors an IL-4–mediated, Th2-dependent aggressive alloimmune response leading to early allograft rejection associated with eosinophilic infiltration.

IL-4–producing Th2 cells were initially believed to mediate protective and protolerogenic functions in the transplant setting.
due to their ability to antagonize Th1 responses. However, particularly in a Th1-deficient environment, this classic Th1/Th2 paradigm had to be questioned based on numerous studies demonstrating Th2-dependent activation of alternative rejection pathways associated with eosinophilic recruitment (6, 20–22). For instance, in bone marrow transplantation, studies by Nikolic et al. (7) in STAT4 and STAT6 knockout mice indicated that both Th1 and Th2 cells contribute to tissue-specific GVHD development particularly when one subset is deficient. Whereas Th1 cells were associated with severe intestinal GVHD, Th2 cells seemed to be critical for hepatic and skin injury in this model. In line with this, Surquin et al. (6) highlighted the importance of IL-4–triggered Th2-mediated solid allograft rejection as they showed prolonged skin allograft survival in IL-4−/− recipients in ∼50% of cases, whereas the remaining animals promptly rejected their skin allografts in a neutrophil-dependent manner. Importantly, these studies are limited by the fact that they have not considered an effector role of Th17 cells in their models, as the significance of pathological Th17 cells in alloimmune responses, particularly in the absence of Th1 differentiation, was discovered after these publications (5, 23, 24). Hence, the neutrophil-mediated skin allograft rejection in the IL-4−/− model (6) might have been caused by alloreactive Th17 cells that emerge in the absence of Th2 allografts. The first study indicating that Th2-mediated alloresponses may mediate an alternate pathway of destructive alloimmune responses in the absence of Th1 and Th17 was published by Yi and colleagues (9). They found that, in bone marrow transplantation, double blockade of Th1 and Th17 using an IL-17/IFN-γ DKO model leads to GVHD idiopathic pneumonia (9). However, this study was limited by the utilization of a cytokine-only deficient model. The IL-17/IFN-γ DKO model cannot eliminate the entire Th1 or Th17 effector capacity because other cytokines produced by these cells, such as TNF-α, IL-21, IL-22, and IL-23, could still mediate pathological effects. Therefore, our study was designed to help close the knowledge gap concerning reciprocal Th cell differentiation in allotransplant responses by exposing the effector roles of alloreactive Th1, Th2, and Th17 cell subsets through the use of genetically modified mice targeting the hallmark Th1 and Th17 transcription factors RORγt and T-bet. Important, we found that T cells doubly deficient for both transcription factors feature diminished levels of IL-17A and IFN-γ, but appreciable levels of IL-4 and GATA-3, which drive early allograft rejection characterized by strong eosinophilic allograft infiltration and intragraft expression of Th2 effector cytokines. Thus, to our knowledge, our study represents the first reported characterization of a solely Th2-driven allograft rejection. Mor-}

FIGURE 3. Double deficiency for T-bet and RORγt promotes Th2-mediated accelerated heart allograft rejection in HTx recipients in vivo. (A) Allograft survival of BALB/c HTx grafted into B6.RAG-γc−/− recipients that were adoptively transferred with T cells from T-bet−/−, RORγt−/−, or RORγt−/−T-bet−/− mice. Controls received no cell transfer (n = 6–8 each). (B) Representative flow cytometry analyses of intracellular IL-17A and IFN-γ as well as (C) IL-4 and GATA-3 expression in splenic CD4+ T cells from rejected/ended HTx recipients after 48 h of ex vivo restimulation with donor-specific CD3+ APCs (gated on viable CD3+CD4+ cells, n = 6). (D) Intragraft mRNA expression levels of IL-4, IL-5, IL-13, GATA-3, and IL-17A in rejected/ended HTx via RT-PCR (n = 5–8 each). (E) Representative histology (H&E staining, scale bars = 20 μm) of rejected heart allografts from the adoptively transferred HTx recipients. *p < 0.05, **p < 0.005, ***p < 0.001.
recipients; allografts from long-surviving animals showed reduced eosinophilic infiltration and low Th2 cytokine levels. Thus, our findings not only illustrate the potency of exclusive Th2-dominated alloresponses in solid organ transplantation, they provide a novel mechanistic tool for comparatively studying Th1, Th2, and Th17 cell differentiation and their respective role in allograft rejection.

In contrast to our findings in solid organ transplantation, Yu et al. (10) recently showed in a bone marrow transplantation model that double deficiency for RORγt and T-bet induces Th2 cell polarization that results in prolonged survival and amelioration of acute GVHD. We speculate that yet unknown bone marrow versus solid organ transplant–specific effects are accountable for this discrepancy. For instance, allorreactive T cells may require a different set of chemokine receptors and homing signals to infiltrate solid organ transplants (i.e., skin and heart) versus GVHD-targeted organs (liver, lung, bowel); this explanation could account for the higher infiltration levels of alloreactive Th2 cells in solid organ transplants observed in our study. Moreover, the process of transplanting a solid organ itself is known to initiate proinflammatory signaling directed toward the allograft that may favor early proinflammatory over regulatory T cell alloresponses. In contrast, it has been shown that T cells doubly deficient for RORγt and T-bet predominantly differentiate into Foxp3+ regulatory T cells in a bone marrow transplantation setting (10). In our study, we failed to detect an

![FIGURE 4.](http://www.jimmunol.org/)
increase in regulatory T cell numbers in transplant recipients with T cells double deficient for RORγt and T-bet (data not shown). Clearly, the mechanistic controversy surrounding the differences observed between the transplant models deserves further investigation. We found that under IL-4-neutralizing conditions, T cells doubly deficient for RORγt and T-bet downregulate GATA-3 expression, but can still reject heart allografts in about one-half of recipients. This raises the question as to the mechanism of the apparent non-Th1/Th2/Th17-mediated allograft rejection. We can exclude the involvement of other Th cell subsets such as Th9 cells, as we failed to detect evidence of IL-9 expression in all transplant recipients. However, whereas we found that IL-17A production was low under IL-4 blockade conditions in DKO mice, a trend toward elevated IFN-γ expression levels in anti–IL-4–treated animals was detected. Further analyses showed that this upregulation of IFN-γ was due to an increase in Eomes-expressing CD4+ T cells. In addition to T-bet, Eomes has been shown to regulate IFN-γ expression in CD8+ T cells and NK cells, and to a lesser degree in CD4+ T cells (25, 26). Consistent with this hypothesis, Yang et al. (26) have shown a critical role for Eomes in regulating IFN-γ expression in activated CD4+ T cells as a compensatory mechanism for T-bet deficiency. Eomes expression in CD4+ T cells is normally masked by Th2 pathways, particularly in the absence of T-bet (26). Consequently, blockade of IL-4 in our model may enable RORγt and T-bet double-deficient CD4+ T cells to overexpress Eomes, which drives Th1-mediated allograft rejection in the absence of T-bet. Mechanistically, it is interesting to note in our in vitro experiments that CD4+ T cells derived from T-bet-/−/− or RORγt-/−/−/T-bet-/−/−/− animals did not produce IFN-γ under Th1-polarizing conditions. However, we attribute this result to the presence of rIL-12 in our cultures, which is known to effectively inhibit Eomes expression (27).

In summary, our data confirm that disrupting T-bet leads to early allograft rejection associated with an enhanced Th2 and Th17 cytokine profile (5). This observation can be ascribed to the key regulatory function of T-bet that promotes Th1 differentiation and simultaneously suppresses Th2 and Th17 polarization (2–4). Consequently, T cells deficient for both RORγt and T-bet exist in a Th1-Th7–deficient environment where Th2-related cytokine production is left unrestrained. Most importantly, although these Th2 favorable conditions have shown mostly protective effects on GVHD after hematopoietic stem cell transplantation (10), we demonstrate in the setting of solid organ transplantation that Th2 cells cause vigorous rejection responses. Further, the current study supports the idea that blockade of IL-4 in RORγt and T-bet deficiency unmasks a compensatory function of Eomes in IFN-γ expression and Th1 differentiation, causing delayed Th1-driven allograft rejection.

Acknowledgments
We thank Lydia Schneider, Kathleen Burghardt, Azucena Martin-Santos, and Irina Kucuk for excellent technical help.

Disclosures
The authors have no financial conflicts of interest.

References
Supplemental Materials

Supplementary Table 1:

(A) Flow cytometry antibodies. (B) Qiagen QuantiTect Primers.
### A

**Flow cytometry antibodies**

<table>
<thead>
<tr>
<th>Localization</th>
<th>Marker</th>
<th>Dye</th>
<th>Reference</th>
<th>Clone</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>surface</td>
<td>CD8</td>
<td>PB</td>
<td>48-0081-82</td>
<td>53-6.7</td>
<td>eBiosciences</td>
</tr>
<tr>
<td></td>
<td>CD8</td>
<td>PE-Cy7</td>
<td>552877</td>
<td>53-6.7</td>
<td>eBiosciences</td>
</tr>
<tr>
<td></td>
<td>CD3</td>
<td>APC-Cy7</td>
<td>47-0032</td>
<td>17A2</td>
<td>eBiosciences</td>
</tr>
<tr>
<td></td>
<td>CD4</td>
<td>APC</td>
<td>17-0041-83</td>
<td>GK1.5</td>
<td>eBiosciences</td>
</tr>
<tr>
<td></td>
<td>CD4</td>
<td>FITC</td>
<td>11-0041-85</td>
<td>GK1.5</td>
<td>eBiosciences</td>
</tr>
<tr>
<td></td>
<td>CD25</td>
<td>APC</td>
<td>17-0251-81</td>
<td>PC61.5</td>
<td>eBiosciences</td>
</tr>
<tr>
<td></td>
<td>CD11b</td>
<td>Pe-Cy7</td>
<td>552850</td>
<td>M1/70</td>
<td>BD Biosciences</td>
</tr>
<tr>
<td></td>
<td>CD11c</td>
<td>APC-Cy7</td>
<td>47-0114-82</td>
<td>N418</td>
<td>eBiosciences</td>
</tr>
<tr>
<td></td>
<td>CD45</td>
<td>FITC</td>
<td>11-0451-82</td>
<td>30F-11</td>
<td>eBiosciences</td>
</tr>
<tr>
<td></td>
<td>Siglec F</td>
<td>PE</td>
<td>552126</td>
<td>E50-2440</td>
<td>BD Biosciences</td>
</tr>
</tbody>
</table>

| intracellular | IL-17A | PB (V450) | 555068 | TC 11-18H10 | BD Biosciences |
|              | IFN-γ  | FITC      | 11-7311-82 | XMG1.2 | eBiosciences |
|              | GATA-3 | PE        | 12-9966-42 | TWAJ  | eBiosciences |
|              | Eomes  | PE        | 12-4875-82 | Dan11mag | eBiosciences |
|              | IL-4   | PE-Cy7    | 25-7042-82 | BVD6-24G2 | eBiosciences |
|              | Foxp3  | PE        | 12-4771-82 | NRRF-36 | eBiosciences |

### B

**Qiagen QuantiTect Primers**

<table>
<thead>
<tr>
<th>No.</th>
<th>Description</th>
<th>Gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>QT00103278</td>
<td>Mm_Il17a_1_SG</td>
<td>IL-17A</td>
</tr>
<tr>
<td>QT00160678</td>
<td>Mm_Il4_1_SG</td>
<td>IL-4</td>
</tr>
<tr>
<td>QT00099715</td>
<td>Mm_Il5_1_SG</td>
<td>IL-5</td>
</tr>
<tr>
<td>QT02423449</td>
<td>Mm_Il13_2_SG</td>
<td>IL-13</td>
</tr>
<tr>
<td>QT01038821</td>
<td>Mm_INFG_1_SG</td>
<td>INF-γ</td>
</tr>
<tr>
<td>QT00170828</td>
<td>Mm_Gata3_1_SG</td>
<td>GATA-3</td>
</tr>
<tr>
<td>QT01658692</td>
<td>Mm_GAPDH_3_SG</td>
<td>GAPDH</td>
</tr>
</tbody>
</table>

**Supplementary Table 1**